Scholarlink

<p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by pruritus, eczematous lesions, and impaired barrier function. Colloidal oatmeal is widely incorporated in over the counter moisturizers used as foundational therapy for AD, yet its clinical and barrier benefits have not been systematically evaluated. We conducted a systematic review and meta-analysis to assess the clinical efficacy and barrier effects of colloidal oatmeal containing formulations in AD. Following Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines, we searched PubMed, Embase, Cochrane Library, Scopus, CINAHL Complete, and ClinicalTrials.gov through August 2025 to identify clinical studies comparing colloidal oatmeal with non oat controls. Only data from two randomized controlled trials (combined <i>n</i> = 139) were available for pooled random effects meta-analysis (DerSimonian and Laird), and remaining studies were synthesized qualitatively. Pooled analysis of the two trials demonstrated equivalent improvement with colloidal oatmeal compared with a prescription barrier repair cream in reducing disease severity (Eczema Area and Severity Index, mean difference = − 0.16 [95% CI − 0.70 to 0.38]; <i>p</i> = 0.56) and itch (visual analog scale, − 0.15 [− 0.68 to 0.38]; <i>p</i> = 0.58), while skin hydration significantly improved with colloidal oatmeal as measured by corneometry (+ 5.85 [4.94 to 6.76]; <i>p</i> &lt; 0.001). Narrative synthesis of 8 additional studies showed consistent enhancements in hydration, transepidermal water loss, skin pH, microbial balance, and quality of life, with favorable tolerability across age groups. Overall, colloidal oatmeal formulations significantly improve hydration and barrier integrity while relieving symptoms in AD, supporting their use as safe, effective, and widely accessible adjunctive therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical efficacy and skin barrier impact of colloidal oatmeal in atopic dermatitis: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年5月20日

查看全文
  • Aashna Farishta,
  • Nicole Bavaro,
  • Christy Chang,
  • Raj Chovatiya

摘要

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by pruritus, eczematous lesions, and impaired barrier function. Colloidal oatmeal is widely incorporated in over the counter moisturizers used as foundational therapy for AD, yet its clinical and barrier benefits have not been systematically evaluated. We conducted a systematic review and meta-analysis to assess the clinical efficacy and barrier effects of colloidal oatmeal containing formulations in AD. Following Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines, we searched PubMed, Embase, Cochrane Library, Scopus, CINAHL Complete, and ClinicalTrials.gov through August 2025 to identify clinical studies comparing colloidal oatmeal with non oat controls. Only data from two randomized controlled trials (combined n = 139) were available for pooled random effects meta-analysis (DerSimonian and Laird), and remaining studies were synthesized qualitatively. Pooled analysis of the two trials demonstrated equivalent improvement with colloidal oatmeal compared with a prescription barrier repair cream in reducing disease severity (Eczema Area and Severity Index, mean difference = − 0.16 [95% CI − 0.70 to 0.38]; p = 0.56) and itch (visual analog scale, − 0.15 [− 0.68 to 0.38]; p = 0.58), while skin hydration significantly improved with colloidal oatmeal as measured by corneometry (+ 5.85 [4.94 to 6.76]; p < 0.001). Narrative synthesis of 8 additional studies showed consistent enhancements in hydration, transepidermal water loss, skin pH, microbial balance, and quality of life, with favorable tolerability across age groups. Overall, colloidal oatmeal formulations significantly improve hydration and barrier integrity while relieving symptoms in AD, supporting their use as safe, effective, and widely accessible adjunctive therapies.